Skip to main content

Table 4 Neurologist network: demographic and clinical data pertaining to seven GBS patients with influenza immunisations during the 42-day period preceding clinical onset

From: Guillain-Barré syndrome following the 2009 pandemic monovalent and seasonal trivalent influenza vaccination campaigns in Spain from 2009 to 2011: outcomes from active surveillance by a neurologist network, and records from a country-wide hospital discharge database

Patient ref. no., sex, age

Vaccination date and type (a)

Co-morbidity or clinical antecedent in 30 days prior to onset

Symptom onset (b)

(a-b) Interval in weeks

Functional level at one week

Treatment

Clinical confirmation on the basis of

1

Female

53

2 Oct 2009

Motor neurone disease

13 Oct 2009

1–2

Walking

Not treated

Clinical symptoms/exam.

2009-TIV

Cerebrospinal fluid (CSF) tests

Electrophysiology lab.

Other causes excluded

2

Male

68

27 Oct 2009

Heart disease.

22 Nov 2009

3–4

Bed-bound

IVGG

Electrophysiology lab.

2009-TIV

Sleep apnea. High blood pressure. Bronchopulmonary infection

Other causes excluded

3

Male

34

20 Oct 2009

Syphilis seropositive

30 Nov 2009

5–6

Walking

IVGG

Clinical symptoms/exam.

2009-TIV

CSF tests

Electrophysiology lab.

Other causes excluded

4

Male

70

28 Sept 2009

Motor neurone disease

10 Oct 2009

1–2

Bed-bound

IVGG

Clinical symptoms/exam

2009-TIV

CSF tests

Electrophysiology lab.

Other causes excluded

5

Male

77

18 Oct 2010

-

1 Nov 2010

2

Bed-bound

IVGG

Clinical symptoms/exam.

2010–2011-TIVa

Electrophysiology lab. Other causes excluded

6

Female

78

5 Jan 2011

-

15 Jan 2011

1–2

Able to walk with support

IVGG

Clinical symptoms/exam.

2010–2011-TIV

CSF tests

Electrophysiology lab. Other causes excluded

7

Male

82

27 Oct 2011

High blood pressure

23 Nov 2011

4

Bed-bound

IVGG Mechanical Ventilation

Clinical symptoms/exam.

2010–2011-TIVa

DM

CSF tests

Atrial fibrillation

Electrophysiology lab. Other causes excluded

  1. GBS Guillain-Barré syndrome, DM diabetes mellitus type 2, TIV seasonal trivalent influenza vaccine, IVGG intravenous gammaglobulin
  2. aReceived the vaccine Chiromas® (Novartis), adjuvanted with MF59C.1